Cargando…

The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology

Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease tha...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kok, Inge M. C. M., Burger, Emily A., Naber, Steffie K., Canfell, Karen, Killen, James, Simms, Kate, Kulasingam, Shalini, Groene, Emily, Sy, Stephen, Kim, Jane J., van Ballegooijen, Marjolein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322998/
https://www.ncbi.nlm.nih.gov/pubmed/32486894
http://dx.doi.org/10.1177/0272989X20924007
_version_ 1783551744388628480
author de Kok, Inge M. C. M.
Burger, Emily A.
Naber, Steffie K.
Canfell, Karen
Killen, James
Simms, Kate
Kulasingam, Shalini
Groene, Emily
Sy, Stephen
Kim, Jane J.
van Ballegooijen, Marjolein
author_facet de Kok, Inge M. C. M.
Burger, Emily A.
Naber, Steffie K.
Canfell, Karen
Killen, James
Simms, Kate
Kulasingam, Shalini
Groene, Emily
Sy, Stephen
Kim, Jane J.
van Ballegooijen, Marjolein
author_sort de Kok, Inge M. C. M.
collection PubMed
description Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease that occurred after screening, 2) disease that was present but not screen detected, or 3) disease that was screen detected but not successfully treated. We examined the relative contributions of each of these using 4 Cancer Intervention and Surveillance Modeling Network (CISNET) models. Methods. The maximum clinical incidence reduction (MCLIR) method compares changes in the number of clinically detected cervical cancers and mortality among 4 scenarios: 1) no screening, 2) one-time perfect screening at age 45 that detects all existing disease and delivers perfect (i.e., 100% effective) treatment of all screen-detected disease, 3) one-time realistic-sensitivity cytological screening and perfect treatment of all screen-detected disease, and 4) one-time realistic-sensitivity cytological screening and realistic-effectiveness treatment of all screen-detected disease. Results. Predicted incidence reductions ranged from 55% to 74%, and mortality reduction ranged from 56% to 62% within 15 years of follow-up for scenario 4 across models. The proportion of deaths due to disease not detected by screening differed across the models (21%–35%), as did the failure of treatment (8%–16%) and disease occurring after screening (from 1%–6%). Conclusions. The MCLIR approach aids in the interpretation of variability across model results. We showed that the reasons why screening failed to prevent cancers and deaths differed between the models. This likely reflects uncertainty about unobservable model inputs and structures; the impact of this uncertainty on policy conclusions should be examined via comparing findings from different well-calibrated and validated model platforms.
format Online
Article
Text
id pubmed-7322998
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73229982020-07-09 The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology de Kok, Inge M. C. M. Burger, Emily A. Naber, Steffie K. Canfell, Karen Killen, James Simms, Kate Kulasingam, Shalini Groene, Emily Sy, Stephen Kim, Jane J. van Ballegooijen, Marjolein Med Decis Making Original Articles Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attributed to 1) (precancerous or cancerous) disease that occurred after screening, 2) disease that was present but not screen detected, or 3) disease that was screen detected but not successfully treated. We examined the relative contributions of each of these using 4 Cancer Intervention and Surveillance Modeling Network (CISNET) models. Methods. The maximum clinical incidence reduction (MCLIR) method compares changes in the number of clinically detected cervical cancers and mortality among 4 scenarios: 1) no screening, 2) one-time perfect screening at age 45 that detects all existing disease and delivers perfect (i.e., 100% effective) treatment of all screen-detected disease, 3) one-time realistic-sensitivity cytological screening and perfect treatment of all screen-detected disease, and 4) one-time realistic-sensitivity cytological screening and realistic-effectiveness treatment of all screen-detected disease. Results. Predicted incidence reductions ranged from 55% to 74%, and mortality reduction ranged from 56% to 62% within 15 years of follow-up for scenario 4 across models. The proportion of deaths due to disease not detected by screening differed across the models (21%–35%), as did the failure of treatment (8%–16%) and disease occurring after screening (from 1%–6%). Conclusions. The MCLIR approach aids in the interpretation of variability across model results. We showed that the reasons why screening failed to prevent cancers and deaths differed between the models. This likely reflects uncertainty about unobservable model inputs and structures; the impact of this uncertainty on policy conclusions should be examined via comparing findings from different well-calibrated and validated model platforms. SAGE Publications 2020-06-03 2020-05 /pmc/articles/PMC7322998/ /pubmed/32486894 http://dx.doi.org/10.1177/0272989X20924007 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
de Kok, Inge M. C. M.
Burger, Emily A.
Naber, Steffie K.
Canfell, Karen
Killen, James
Simms, Kate
Kulasingam, Shalini
Groene, Emily
Sy, Stephen
Kim, Jane J.
van Ballegooijen, Marjolein
The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
title The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
title_full The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
title_fullStr The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
title_full_unstemmed The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
title_short The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
title_sort impact of different screening model structures on cervical cancer incidence and mortality predictions: the maximum clinical incidence reduction (mclir) methodology
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322998/
https://www.ncbi.nlm.nih.gov/pubmed/32486894
http://dx.doi.org/10.1177/0272989X20924007
work_keys_str_mv AT dekokingemcm theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT burgeremilya theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT nabersteffiek theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT canfellkaren theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT killenjames theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT simmskate theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT kulasingamshalini theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT groeneemily theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT systephen theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT kimjanej theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT vanballegooijenmarjolein theimpactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT dekokingemcm impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT burgeremilya impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT nabersteffiek impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT canfellkaren impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT killenjames impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT simmskate impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT kulasingamshalini impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT groeneemily impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT systephen impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT kimjanej impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology
AT vanballegooijenmarjolein impactofdifferentscreeningmodelstructuresoncervicalcancerincidenceandmortalitypredictionsthemaximumclinicalincidencereductionmclirmethodology